During the past year, HeartKinetics has achieved significant milestones with the start of several clinical trials and the publication of KINO.cardio app on the application stores (Google Play and App Store) for this purpose. To help enable the expansion of its KINO® solutions, HeartKinetics has now strengthened its Clinical Steering Committee, representing by a collection of some of the world’s most renowned and pioneering experts in cardiology and HF.
“We are honored to have such esteemed experts on our board and the advisors will help us take KINO® solution to the next level,” said Pierre-François Migeotte, CEO at HeartKinetics. “All of them truly embrace and align with our mission to bring reliable, accurate solutions to revolutionize the management of HF, one of the leading causes of death worldwide with nearly 65 million cases recorded. As we advance our clinical mission, we are grateful for the valuable perspectives, insights, and encouragement they each bring as we tackle new challenges and opportunities on our path toward commercialization in the USA and Europe. This Clinical Steering Committee will bring confidence to all HeartKinetics stakeholders.”
“We truly believe that the KINOcardiography will change the way we can monitor many of our cardiac patients. I am glad to help in the clinical validation program of the technology of Heartkinetics” said Prof. Stephane Carlier. “HeartKinetics offers solutions that may revolutionize the field of HF. KINO.cardio has the impact to change the way we manage HF patients nowadays” completed Prof. Gianluigi Savarese.
Since its creation in 2019, Heartkinetics has always put science at the heart of its development. This major milestone demonstrates the aim to build a clinical and regulatory validation program that meets the expectations of all market players: from the pharmaceutical industry active in the development of the next generation HF drugs to our future customers (hospitals and clinics) and our investor network.
Professor Stefan Anker – President of HeartKinetics Clinical Steering Committee; CHF and Cachexia International Expert, Charité Hospital – Berlin, DE
Prof Stefan Anker is professor of (Tissue) Homeostasis in Cardiology & Metabolism at Charité Berlin, Germany, since June 2017. Prodigious researcher who has authored more than 1,000 articles. He has also won several prizes, including the 2018 Copernicus Prize of German DFG & Polish FNP. In October 2020, he was awarded a Doctor honoris causa of Medical University Wroclaw, Poland. Prof Anker has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006 and was HFA President from 2012 to 2014. He currently chairs the HFA committee on regulatory affairs. He is founding Editor-in-Chief of the first open-access HF journal, ESC Heart Failure. Prof. Anker has served on several ESC Guideline task forces.
Professor Shelley Zieroth – President of the Canadian HF Association – Toronto, CA
Prof. Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the HF and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several HF clinical trials as a Principal Investigator, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada.
Professor Javed Butler – Prof Chair. Dept. of Medicine, FDA Advisor University of Mississippi Medical Center – MS, USA
Javed Butler, MD, MPH, MBA, is the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi. He received his medical degree from the Aga Khan University, residency training at Yale University, cardiology and HF and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital. He has completed MPH from Harvard and MBA from Emory. Dr. Butler is board certified in Cardiology and in HF and transplant medicine. He had received Simon Dack Award from ACC and Time, Feeling, and Focus Award from AHA. He has authored more than 750 peer-reviewed publications.
Professor Stéphane Carlier – Prof. of cardiology CHU ambroise pare – Mons, BE
Stéphane Carlier received his MD degree from the Université Libre de Bruxelles (Belgium) in 1996 and defended his PhD in Biomedical Engineering at Erasmus University, Rotterdam (Netherlands) in 2001. He is currently interventional cardiologist at the University Hospital Ambroise Paré, Mons (Belgium), and professor of Cardiology at UMons. He held previously the position of Assistant Professor of Clinical Medicine and Bioengineering at the Columbia University, New York (NY) and was the Director of the Intravascular Imaging & Physiology Corelab of the Cardiovascular Research Foundation. His research interests include new intravascular imaging, cardiac and vascular dynamics, physiology and signal processing. He serves on several reviewing boards of medical and bioengineering journals.
Professor Gianluigi Savarese – Prof. of Cardiology Karolinska Institute – Stockholm, SW
Gianluigi Savarese is currently Associate Professor of Cardiology at Karolinska Institute and Consultant for HF at the Karolinska University Hospital, Stockholm, Sweden. Over the last 5 years he has published around 150 scientific works on top peer-reviewed journals focusing mainly on HF, epidemiology and CV pharmacotherapy. He is expert in registry-based studies and trials.
Professor Frederik Hendrik Verbrugge – HF cardiologist, Dir. Dyspnea Clinic UZ Brussels, BE
Frederik H. Verbrugge is a Cardiologist physician with dedicated interest in HF, (exercise) hemodynamics & cardiorenal physiology. Prof. Dr. Verbrugge graduated as M.D. in 2010 (KU Leuven, Belgium), obtained his Ph.D. in 2015 (Hasselt University, Belgium) & received an M.Sc. in Clinical Trials in 2022 (Oxford University, UK). He is currently employed as Clinic Head/Clinical Professor at University Hospital Brussels/Vrije Universiteit Brussel (Belgium), where he cares for patients with HF & cardiac devices, attends the cardiac intensive care unit, and runs the exercise physiology lab. For his research, Prof. Dr. Verbrugge has an affiliation with the Department of Cardiovascular Diseases of the Mayo Clinic (Rochester, MN, US). He currently serves as Deputy Editor for European Heart Journal: Acute Cardiovascular Care and Editorial Consultant for JACC: Heart Failure.
HeartKinetics is a Medtech company specialized in the research, development and commercialization of remote detection and monitoring solutions for heart failure. HeartKinetics is revolutionizing cardiovascular diseases and patient management worldwide thanks to AI-based predictive technology able to intercept heart failure. KINO® is the first solution the company brings to the market (CE mark and FDA agreement are under approval). It combines a mobile self-management app for heart failure patients, a web platform that supports decision-making of healthcare professionals as well as a cloud computing space where the AI-based technology turns data into predictive actionable insights for treatment efficacy.
About KINO®
For cardiologists and general practitioners who need to intercept heart failure, KINO provides a fully integrated patient-centered solution where actionable cardio-haemodynamic data collected with a smartphone is supercharged by AI to detect early signs of decompensation and prevent hospitalizations.
The KINO.cardio app has not been evaluated by the FDA for safety or effectiveness. The KINO.cardio app is currently not available for sale in the USA and Europe.
